NCT03933696View on ClinicalTrials.gov

Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Mild Cognitive ImpairmentAlzheimer DiseaseType2 Diabetes
Interventions
DEVICE

Tailored Lighting Intervention

Lighting Intervention either Active or Placebo

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

08854

Rutgers University, New Brunswick

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT03933696 - Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2 | Biotech Hunter | Biotech Hunter